Professor | Mingliang Wang | Asia Growth Partners

Name	Mingliang Wang
Contact Information	wangmingliang@simm.ac.cn
Language ability	Chinese, English
Province	Shanghai

Name

Mingliang Wang

Contact Information

wangmingliang@simm.ac.cn

Language ability

Chinese, English

Province

Shanghai

University/Lab Affiliation and Title	University of Chinese Academy of Sciences
Faculty	Medical School
Academic Background & Achievements	2013-09--2017-06 Ph.D.: Fudan University 2004-09--2006-06 Master's Degree: Wuhan University 1999-09--2003-06 Bachelor's Degree: Wuhan Institute of Technology
Work Experience	2021-03~Present - Chinese Academy of Sciences Shanghai Institute of Materia Medica - Researcher, Group Leader 2017-07~2020-11 - University of Michigan, Ann Arbor - Postdoctoral Researcher 2011-05~2013-09 - GlaxoSmithKline Shanghai R&D Center - Medicinal Chemist 2006-07~2011-05 - Shanghai ChemPartner Co., Ltd. - Senior Organic Synthesis Researcher, Group Leader

University/Lab Affiliation and Title

University of Chinese Academy of Sciences

Faculty

Medical School

Academic Background & Achievements

2013-09--2017-06 Ph.D.: Fudan University
2004-09--2006-06 Master's Degree: Wuhan University
1999-09--2003-06 Bachelor's Degree: Wuhan Institute of Technology

Work Experience

2021-03~Present - Chinese Academy of Sciences Shanghai Institute of Materia Medica - Researcher, Group Leader
2017-07~2020-11 - University of Michigan, Ann Arbor - Postdoctoral Researcher
2011-05~2013-09 - GlaxoSmithKline Shanghai R&D Center - Medicinal Chemist
2006-07~2011-05 - Shanghai ChemPartner Co., Ltd. - Senior Organic Synthesis Researcher, Group Leader

Areas of Focus	Development of new drugs targeting protein degraders Development of new allosteric inhibitors
Publications	Discovery of a Covalent Inhibitor Selectively Targeting the Autophosphorylation Site of c-Src Kinase, 10th Author, 2024 Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity Against AR Mutants for the Treatment of AR+ Human Prostate Cancer, 9th Author, 2023 Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity, 6th Author, 2023 Discovery of PVD-06 as a Subtype-Selective and Efficient PTPN2 Degrader, 10th Author, Corresponding Author, 2023 E3 ligase ligand optimization of Clinical PROTACs, 11th Author, 2023 (-)-Epigallocatechin Gallate is a Noncompetitive Inhibitor of NAD Kinase, 7th Author, 2022 The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay, 11th Author, 2022 Metal-free photo-induced sulfidation of aryl iodide and other chalcogenation, 11th Author, 2022 Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1, 5th Author, 2022 Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer, 12th Author, 2022 Intramolecular N-Me and N-H Aminoetherification for the Synthesis of N-Unprotected 3-Amino-O-Heterocycles, 2nd Author, 2021 Pharmacological inhibition of SRC-1 phase separation suppresses YAP oncogenic transcription activity, 4th Author, 2021 Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein, 1st Author, 2020 Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER), 3rd Author, 2019 Effective approach to ureas through organocatalyzed one-pot process, 1st Author, 2018 Discovery of novel 1,2,3,4-tetrahydrobenzo4, 5thieno2, 3-cpyridine derivatives as potent and selective CYP17 inhibitors, 1st Author, 2017 Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment, 4th Author, 2017 Divergent copper-mediated dimerization and hydroxylation of benzamides involving C-H bond functionalization, 1st Author, 2016 Fluorination of 2-substituted benzo[b]furans with Selectfluor, 1st Author, 2015

Areas of Focus

Development of new drugs targeting protein degraders
Development of new allosteric inhibitors

Publications

Discovery of a Covalent Inhibitor Selectively Targeting the Autophosphorylation Site of c-Src Kinase, 10th Author, 2024
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity Against AR Mutants for the Treatment of AR+ Human Prostate Cancer, 9th Author, 2023
Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity, 6th Author, 2023
Discovery of PVD-06 as a Subtype-Selective and Efficient PTPN2 Degrader, 10th Author, Corresponding Author, 2023
E3 ligase ligand optimization of Clinical PROTACs, 11th Author, 2023
(-)-Epigallocatechin Gallate is a Noncompetitive Inhibitor of NAD Kinase, 7th Author, 2022
The discovery of a non-competitive GOT1 inhibitor, hydralazine hydrochloride, via a coupling reaction-based high-throughput screening assay, 11th Author, 2022
Metal-free photo-induced sulfidation of aryl iodide and other chalcogenation, 11th Author, 2022
Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1, 5th Author, 2022
Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer, 12th Author, 2022
Intramolecular N-Me and N-H Aminoetherification for the Synthesis of N-Unprotected 3-Amino-O-Heterocycles, 2nd Author, 2021
Pharmacological inhibition of SRC-1 phase separation suppresses YAP oncogenic transcription activity, 4th Author, 2021
Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein, 1st Author, 2020
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER), 3rd Author, 2019
Effective approach to ureas through organocatalyzed one-pot process, 1st Author, 2018
Discovery of novel 1,2,3,4-tetrahydrobenzo4, 5thieno2, 3-cpyridine derivatives as potent and selective CYP17 inhibitors, 1st Author, 2017
Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment, 4th Author, 2017
Divergent copper-mediated dimerization and hydroxylation of benzamides involving C-H bond functionalization, 1st Author, 2016
Fluorination of 2-substituted benzo[b]furans with Selectfluor, 1st Author, 2015

Protein Degraders Drug Development Allosteric Inhibitors Medicinal Chemistry Targeted Therapy Cancer Treatment Biochemistry Pharmacology Molecular Biology Chemical Biology

Jin Tang Dong - Southern University of Science and Technology

Ning Jia - Southern University of Science and Technology

Ji Yang - Southern University of Science and Technology

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us